Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.[7][8]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Human |
Target | IL23 |
Clinical data | |
Trade names | Tremfya |
AHFS/Drugs.com | Monograph |
MedlinePlus | a617036 |
License data |
|
Pregnancy category |
|
Routes of administration | Subcutaneous |
ATC code |
|
Legal status | |
Legal status | |
Identifiers | |
CAS Number |
|
DrugBank |
|
ChemSpider |
|
UNII |
|
KEGG |
|
Chemical and physical data | |
Formula | C6402H9864N1676O1994S42 |
Molar mass | 143561.59 g·mol−1 |
Guselkumab is indicated to treat moderate to severe plaque psoriasis, and psoriatic arthritis in adults.[5]
Guselkumab is provided as a subcutaneous injection of 100 mg given every eight weeks (except for the second dose, which is given four weeks after the first dose).[9]
Because guselkumab lowers the release of immune system signalling molecules, patients may have a higher risk of getting infections from bacteria, viruses, and fungi.[7] For this reason, people with psoriasis being considered for treatment with guselkumab must be screened for tuberculosis infection prior to treatment with guselkumab.[7]
The most common side effects for guselkumab are upper respiratory tract infections, headache, injection site reactions,[10] joint pain, diarrhea, gastroenteritis, fungal skin infections and herpes simplex infections.[11] Because guselkumab is a new medicine, the long-term effects are not fully understood.[12]
Guselkumab targets the IL-23 subunit alpha (p19 subunit)[13] preventing it from binding to cell receptors that would otherwise be activated by its presence.[14]
Guselkumab was developed by Janssen Global Services, LLC.[15] In November 2016, Janssen submitted a Biologics License Application (BLA) to the FDA seeking approval of guselkumab.[16]
In July 2017, Janssen gained US FDA approval to market guselkumab for treatment of plaque psoriasis.[17]
In November 2017 Health Canada approved guselkumab to be marketed for the treatment of plaque psoriasis in Canada. [18] In September 2020 approval was expanded to include the treatment of adults with psoriatic arthritis. [19]
In April 2018, guselkumab was approved in Japan for the treatment psoriatic arthritis.[20]
In July 2020, the FDA approved as the first IL-23 inhibitor to treat active psoriatic arthritis (PsA) in the USA. [21][22]
Guselkumab is manufactured by Janssen Sciences Ireland UC in Cork, Ireland.[23]
The list price of each 100 mg dose (to be given once every two months) is about $10,000.[24]
During development, guselkumab was referred to as CNTO-1959.[14] Guselkumab has undergone phase 3 clinical trials comparing it with adalimumab (Humira) and ustekinumab (Stelara).[15]
The safety and efficacy of guselkumab was compared to a placebo and to adalimumab in the "VOYAGE 1" and "VOYAGE 2" phase 3 clinical trials (ClinicalTrials.gov IDs: NCT02207231 and NCT02207244).[12] Preliminary results indicated that a significantly higher proportion of patients taking guselkumab had better skin clearance compared to those taking the other treatments. At week 16, 73.3% of patients taking guselkumab achieved a PASI 90 (90% reduction in PASI score from baseline), vs 49.7% of those taking adalimumab; additionally, 91.2% of patients taking guselkumab achieved a PASI 75 (75% reduction in PASI score from baseline), vs 73.1% of those taking adalimumab.[12]
The phase III clinical trial "NAVIGATE" (ClinicalTrials.gov ID: NCT02203032) included only patients who had poor responses to treatment with ustekinumab. It showed that patients who switched to guselkumab from ustekinumab did better than those who remained on ustekinumab.[14]